Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups

Zhang,Qiao; Cui,Yanyan; Zhang,Jian; Kenjiabieke,Jiayideng; Aerxiding,Patiguli

doi:10.3892/etm.2020.8612

Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups

Authors:
- Qiao Zhang
- Yanyan Cui
- Jian Zhang
- Jiayideng Kenjiabieke
- Patiguli Aerxiding
View Affiliations

Affiliations: Department of Thoracic Oncology, The Third Clinical Medical College of Xinjiang Medical University, The Affiliated Tumor Hospital Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Geriatric, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832000, P.R. China, Outpatient Department, People's Liberation Army 69260 Troops of Medical Team, Urumqi, Xinjiang 830002, P.R. China
Published online on: March 19, 2020 https://doi.org/10.3892/etm.2020.8612
Pages: 3513-3520
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with epidermal growth factor receptor (EGFR)‑sensitive mutations generally have a significantly higher objective response rate (ORR) and longer progression‑free survival (PFS) after EGFR‑tyrosine kinase inhibitor (TKI) treatment. However, the efficacy of EGFR‑TKIs in the case of uncommon EGFR mutations has remained elusive. In the present study, the characteristics of uncommon EGFR mutations and EGFR‑TKI treatments were compared in patients with non‑small cell lung cancer (NSCLC) from different ethnic groups. A total of 2,984 patients with pathologically confirmed NSCLC encountered between February 2012 to February 2017 at the Affiliated Tumor Hospital of Xinjiang Medical University (Urumqi, China) were enrolled in the present study. The Amplification Refractory Mutation System was adopted to determine EGFR gene expression, compare the ethnic differences in EGFR mutations between Xinjiang Uygur and Han people, analyze the distribution of uncommon mutation types and evaluate the link between clinicopathological features associated with uncommon mutations and the efficacy of EGFR‑TKI treatment. There were significant differences in EGFR mutations in lung adenocarcinoma and lung squamous cell carcinoma between patients from the Xinjiang Uygur group and the Han group (P<0.001). The differences in the uncommon EGFR mutations were significant in patients with lung adenocarcinoma (P<0.05). The most common site of lymph node metastasis in patients with uncommon mutations was the hilar lymph node, supraclavicular/subclavian lymph node, cervical lymph node and mediastinal lymph node; the most common distant metastatic organs were the lung, bone, brain, liver and adrenal gland. Of the uncommon mutations, the most common single mutations were L861Q, G719X and 20ins mutations; the most common double mutation was the S768I and 20ins mutation. The incidence rate of EGFR gene mutations was significantly higher in Han people from Xinjiang than in Uygur people. There were marked differences between individuals regarding the efficacy of EGFR‑TKI treatment and the survival time of patients with uncommon EGFR mutations, second‑line EGFR‑TKIs had a lower ORR and DCR while had a longer mPFS. All of these could provide a basis for the exploration of different regimens for patients with different types of uncommon mutations.

View Figures

View References

1	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–500. 2004.PubMed/NCBI View Article : Google Scholar
2	Brooks DL, Wakefield L and Steeg P: Abstract 4859: The role of LPAR1 and fibrosis in breast cancer metastasis. Cancer Res. 77:4859. 2017.
3	Wang Y, Zhu B, Ye M and Chen Z: Study on relationship between VEGF-C and lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 9:182–186. 2006.(In Chinese). PubMed/NCBI View Article : Google Scholar
4	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
5	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010.PubMed/NCBI View Article : Google Scholar
6	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011.PubMed/NCBI View Article : Google Scholar
7	Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Manríquez MEV, Covián-Molina E, Martínez-Barrera L, Meneses A, Cardona A and Borbolla-Escoboza JR: Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 7:1228–1234. 2012.PubMed/NCBI View Article : Google Scholar
8	Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin E, Kirchuk R, et al: Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 6:1955–1959. 2011.PubMed/NCBI View Article : Google Scholar
9	Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, Persigehl T, Jeon YK and Chung DH: Epidermal growth factor receptor mutation in lung adenocarcinomas: Relationship with CT characteristics and histologic subtypes. Radiology. 268:254–264. 2013.PubMed/NCBI View Article : Google Scholar
10	Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, Hisamoto A, Kiura K and Takigawa N: Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Onco Targets Ther. 6:155–160. 2013.PubMed/NCBI View Article : Google Scholar
11	Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009.PubMed/NCBI View Article : Google Scholar
12	Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005.PubMed/NCBI View Article : Google Scholar
13	Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D and Georgoulias V: ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 97:1560–1566. 2007.PubMed/NCBI View Article : Google Scholar
14	Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, et al: Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget. 8:32626–32638. 2017.PubMed/NCBI View Article : Google Scholar
15	Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H and Han B: EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer. 96:87–92. 2016.PubMed/NCBI View Article : Google Scholar
16	Chen D, Song Z and Cheng G: Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 9:4181–4186. 2016.PubMed/NCBI View Article : Google Scholar
17	Kuiper JL, Hashemi SMS, Thunnissen E, Snijders PJF, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA and Smit EF: Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 115:1504–1512. 2016.PubMed/NCBI View Article : Google Scholar
18	Zhou J and Ben S: Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Thoracic Cancer. 9:228–233. 2018.PubMed/NCBI View Article : Google Scholar
19	Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ and Feng JF: Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncol Rep. 29:1975–1982. 2013.PubMed/NCBI View Article : Google Scholar
20	Rahman S, Kondo N, Yoneda K, Takuwa T, Hashimoto M, Orui H, Okumura Y, Tanaka F, Kumamoto K, Mostafa MG, et al: Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. Int J Clin Oncol. 19:45–49. 2014.PubMed/NCBI View Article : Google Scholar
21	Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, et al: EGFR and KRAS mutations in lung carcinomas in the Dutch population: Increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dodr). 35:189–196. 2012.PubMed/NCBI View Article : Google Scholar
22	Zhou D: Detection of EGFR mutation by DHPLC analysis in Chinese NSCLC and colorectal carcinoma patients and its clinical implication. Oncol Prog, 2006.
23	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC Cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.PubMed/NCBI View Article : Google Scholar
24	Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K and Shimada Y: Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer. 3:128–133. 2000.PubMed/NCBI View Article : Google Scholar
25	Machnicki MM, Glodkowska-Mrowka E, Lewandowski T, Ploski R, Wlodarski P and Stoklosa T: ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques. Acta Biochim Pol. 60:57–64. 2013.PubMed/NCBI
26	Chu H, Zhong C, Xue G, Liang X, Wang J, Liu Y, Zhao S, Zhou Q and Bi J: Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncol Rep. 30:2311–2315. 2013.PubMed/NCBI View Article : Google Scholar
27	Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S and Kikuchi K: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 7:603–610. 2000.PubMed/NCBI View Article : Google Scholar
28	Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37 (Suppl 4):S9–S15. 2001.PubMed/NCBI View Article : Google Scholar
29	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
30	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007.PubMed/NCBI View Article : Google Scholar
31	Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB: Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 8:45–51. 2013.PubMed/NCBI View Article : Google Scholar
32	Wang S and Wang Z: EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: A meta-analysis. Int J Clin Exp Med. 7(1967)2014.PubMed/NCBI
33	Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, Wang S, Yang L, An T, Zhang Y, et al: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 67:343–347. 2010.PubMed/NCBI View Article : Google Scholar
34	Sonobe M, Manabe T, Wada H and Tanaka F: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 93:355–363. 2005.PubMed/NCBI View Article : Google Scholar
35	Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11:217–227. 2007.PubMed/NCBI View Article : Google Scholar
36	Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, et al: Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 10:793–799. 2015.PubMed/NCBI View Article : Google Scholar
37	Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY and Yang PC: Effectiveness of tyrosine kinase inhibitors on ‘uncommon’ epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 17:3812–3821. 2011.PubMed/NCBI View Article : Google Scholar
38	Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010.PubMed/NCBI View Article : Google Scholar
39	Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, et al: Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res. 21:642–651. 2015.PubMed/NCBI View Article : Google Scholar
40	Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, et al: Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 9:189–194. 2014.PubMed/NCBI View Article : Google Scholar